{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:27:42Z","timestamp":1787149662948,"version":"build-2736575974"},"reference-count":30,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,11,10]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1136\/ejhpharm-2025-004604","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:00:56Z","timestamp":1774587656000},"page":"423-430","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["A pharmacist-led intervention to promote the uptake of an infliximab biosimilar by patients and physicians in a university hospital rheumatology unit"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-130X","authenticated-orcid":false,"given":"Marion","family":"Duwez","sequence":"first","affiliation":[{"name":"Pharmacy, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Bonnabry","sequence":"additional","affiliation":[{"name":"Pharmacy, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Institute of Pharmaceutical Sciences of Western Switzerland, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"2026081906551085000_33.5.423.1","unstructured":"World Health Organization . Health topics: biologicals. Available: https:\/\/www.who.int [Accessed 16 Feb 2025]."},{"key":"2026081906551085000_33.5.423.2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/14737167.2022.2117690","article-title":"The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States","volume":"22","author":"Ding","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026081906551085000_33.5.423.3","unstructured":"European Medicines Agency . Biosimilars in the EU: information guide for healthcare professionals. 2019. Available: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf [Accessed 16 Feb 2025]."},{"key":"2026081906551085000_33.5.423.4","unstructured":"Intergenerika . Barom\u00e8tres des biosimilaires. 2024. Available: https:\/\/www.intergenerika.ch\/fr\/content\/download\/1078\/31492\/1?fileName=240416_Biosimilar-Barometer_FR.pdf [Accessed 16 Feb 2025]."},{"key":"2026081906551085000_33.5.423.5","unstructured":"IQVIA Institute for Human Data Science . The global use of medicine in 2024 and outlook to 2028. Available: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/the-global-use-of-medicines-2024-outlook-to-2028\/iqvia-institute-global-use-of-medicines-2024-forweb.pdf [Accessed 16 Feb 2025]."},{"key":"2026081906551085000_33.5.423.6","unstructured":"Office F\u00e9d\u00e9ral de la Statistique (OFS) . Co\u00fbt et financement du syst\u00e8me de sant\u00e9 en 2022. 2024. Available: https:\/\/www.bfs.admin.ch\/asset\/fr\/31225974 [Accessed 16 Feb 2025]."},{"key":"2026081906551085000_33.5.423.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077454","article-title":"Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting","volume":"13","author":"Wirth","year":"2023","journal-title":"BMJ Open"},{"key":"2026081906551085000_33.5.423.8","unstructured":"Federal Office of Public Health . Le conseil f\u00e9d\u00e9ral favorise les g\u00e9n\u00e9riques et l\u2019acc\u00e8s aux m\u00e9dicaments vitaux. 2023. Available: https:\/\/www.bag.admin.ch\/bag\/fr\/home\/das-bag\/aktuell\/medienmitteilungen.msg-id-97800.html [Accessed 16 Feb 2025]."},{"key":"2026081906551085000_33.5.423.9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40259-023-00620-7","article-title":"Patients\u2019 Perceptions of Biosimilars: A Systematic Review","volume":"37","author":"Wu","year":"2023","journal-title":"BioDrugs"},{"key":"2026081906551085000_33.5.423.10","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00296-021-04874-8","article-title":"Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study","volume":"42","author":"Chew","year":"2022","journal-title":"Rheumatol Int"},{"key":"2026081906551085000_33.5.423.11","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.dld.2019.08.020","article-title":"Patients\u2019 perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study","volume":"51","author":"Petitdidier","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2026081906551085000_33.5.423.12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bcpt.13719","article-title":"\u201cBiosimilar, so it looks alike, but what does it mean?\u201d A qualitative study of Danish patients\u2019 perceptions of biosimilars","volume":"130","author":"Varma","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026081906551085000_33.5.423.13","article-title":"Patient\u2019s and Consultant\u2019s Views and Perceptions on Switching from an Originator Biologic to Biosimilar Medication: A Qualitative Study","volume":"12","author":"Rosembert","year":"2024","journal-title":"Pharmacy (Basel)"},{"key":"2026081906551085000_33.5.423.14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40259-020-00452-9","article-title":"European Stakeholder Learnings Regarding Biosimilars: Part I\u2014Improving Biosimilar Understanding and Adoption","volume":"34","author":"Barbier","year":"2020","journal-title":"BioDrugs"},{"key":"2026081906551085000_33.5.423.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2019.01.001"},{"key":"2026081906551085000_33.5.423.16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40259-024-00659-0","article-title":"Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review","volume":"38","author":"Rieger","year":"2024","journal-title":"BioDrugs"},{"key":"2026081906551085000_33.5.423.17","doi-asserted-by":"crossref","first-page":"105322","DOI":"10.1016\/j.jbspin.2021.105322","article-title":"Impact of a clinical pharmacist in a multidisciplinary consultation on the switch to a biosimilar for inflammatory rheumatic diseases","volume":"89","author":"Levivien","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2026081906551085000_33.5.423.18","unstructured":"Creswell JW , Creswell JD . Qualitative methods. In: Felts DC , ed. Research design: qualitative, quantitative, and mixed methods approaches. London: Sage Publications, 2018: 185\u201390. Available: https:\/\/books.google.ch\/books\/about\/Research_Design.html?id=335ZDwAAQBAJ&redir_esc=y"},{"key":"2026081906551085000_33.5.423.19","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2026081906551085000_33.5.423.20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001396","article-title":"Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar","volume":"7","author":"Petit","year":"2021","journal-title":"RMD Open"},{"key":"2026081906551085000_33.5.423.21","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3390\/healthcare10112152","article-title":"Current Expertise, Opinions, and Attitude toward TNF-\u237a Antagonist Biosimilars among Physicians: A Self-Administered Online Survey in Western Switzerland","volume":"10","author":"Krstic","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2026081906551085000_33.5.423.22","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-022-00309-4","article-title":"Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions","volume":"6","author":"Khoo","year":"2022","journal-title":"BMC Rheumatol"},{"key":"2026081906551085000_33.5.423.23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40290-024-00541-y","article-title":"Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review","volume":"38","author":"Car","year":"2024","journal-title":"Pharm Med"},{"key":"2026081906551085000_33.5.423.24","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40259-020-00440-z","article-title":"European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice","volume":"34","author":"Barbier","year":"2020","journal-title":"BioDrugs"},{"key":"2026081906551085000_33.5.423.25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1248\/bpb.b22-00429","article-title":"Factors Affecting Patients\u2019 Acceptance of Switching to Biosimilars Are Disease-Dependent: A Cross-Sectional Study","volume":"46","author":"Funaki","year":"2023","journal-title":"Biol Pharm Bull"},{"key":"2026081906551085000_33.5.423.26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40801-022-00299-2","article-title":"Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data","volume":"9","author":"Krstic","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"2026081906551085000_33.5.423.27","first-page":"952","article-title":"The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies","volume":"24","author":"Odinet","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"2026081906551085000_33.5.423.28","doi-asserted-by":"crossref","first-page":"820755","DOI":"10.3389\/fmed.2022.820755","article-title":"Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging","volume":"9","author":"Barbier","year":"2022","journal-title":"Front Med"},{"key":"2026081906551085000_33.5.423.29","unstructured":"Federal Office of Public Health . Les biosimilaires sont substituables aux originaux. 2023. Available: https:\/\/www.bag.admin.ch\/bag\/fr\/home\/das-bag\/aktuell\/news\/news-22-06-2023.html [Accessed 16 Feb 2025]."},{"key":"2026081906551085000_33.5.423.30","doi-asserted-by":"crossref","DOI":"10.2196\/56553","article-title":"An Educational Digital Tool to Improve the Implementation of Switching to a Biosimilar (Rapid Switch Trainer): Tool Development and Validation Study","volume":"8","author":"Marras","year":"2024","journal-title":"JMIR Form Res"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2025-004604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:56:00Z","timestamp":1787147760000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2025-004604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/ejhpharm-2025-004604"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2025-004604","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]}}}